|37.51||+0.3600||+0.97%||Vol 406.27K||1Y Perf 67.41%|
|Jul 30th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||43.50||Analyst Rating||Strong Buy 1.09|
|Potential %||15.97||Finscreener Ranking||★★ 46.75|
|Insiders Trans % 3/6/12 mo.||-100/-100/-98||Value Ranking||★+ 43.87|
|Insiders Value % 3/6/12 mo.||-100/-100/-99||Growth Ranking||★★ 46.29|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-99||Income Ranking||— -|
|Market Cap||2.88B||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||88.87||Earnings Date||5th Aug 2021|
Today's Price Range
5 Year PE Ratio Range
|5 Years||1 068.54%|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th Aug 2021|
|Estimated EPS Next Report||0.51|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||422.57K|
|Avg. Monthly Volume||691.56K|
|Avg. Quarterly Volume||720.91K|
Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA) stock closed at 37.51 per share at the end of the most recent trading day (a 0.97% change compared to the prior day closing price) with a volume of 406.97K shares and market capitalization of 2.88B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 302 people. Dicerna Pharmaceuticals Inc. CEO is Douglas M. Fambrough.
The one-year performance of Dicerna Pharmaceuticals Inc. stock is 67.41%, while year-to-date (YTD) performance is 70.27%. DRNA stock has a five-year performance of 1068.54%. Its 52-week range is between 16.5 and 40.14, which gives DRNA stock a 52-week price range ratio of 88.87%
Dicerna Pharmaceuticals Inc. currently has a PE ratio of -23.40, a price-to-book (PB) ratio of 22.82, a price-to-sale (PS) ratio of 20.69, a price to cashflow ratio of 10.90, a PEG ratio of 2.32, a ROA of -15.90%, a ROC of -65.26% and a ROE of -76.17%. The company’s profit margin is -63.88%, its EBITDA margin is -66.20%, and its revenue ttm is $137.43 Million , which makes it $1.79 revenue per share.
Of the last four earnings reports from Dicerna Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $0.51 for the next earnings report. Dicerna Pharmaceuticals Inc.’s next earnings report date is 05th Aug 2021.
The consensus rating of Wall Street analysts for Dicerna Pharmaceuticals Inc. is Strong Buy (1.09), with a target price of $43.5, which is +15.97% compared to the current price. The earnings rating for Dicerna Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Dicerna Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Dicerna Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.28, ATR14 : 1.70, CCI20 : -44.28, Chaikin Money Flow : 0.15, MACD : 0.43, Money Flow Index : 52.89, ROC : -3.52, RSI : 52.34, STOCH (14,3) : 46.87, STOCH RSI : 0.69, UO : 46.59, Williams %R : -53.13), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Dicerna Pharmaceuticals Inc. in the last 12-months were: Adam M. Koppel (Option Excercise at a value of $0), Adam M. Koppel (Sold 1 000 000 shares of value $23 400 000 ), Anna Protopapas (Option Excercise at a value of $0), Bob Brown (Option Excercise at a value of $1 157 201), Bob Brown (Sold 196 656 shares of value $5 104 847 ), Bob D. Brown (Option Excercise at a value of $870 300), Bob D. Brown (Sold 158 235 shares of value $4 369 578 ), Cynthia Smith (Option Excercise at a value of $0), Douglas M. Fambrough (Buy at a value of $180 597), Douglas M. Fambrough (Option Excercise at a value of $0), Douglas W. Pagan (Option Excercise at a value of $0), J. Kevin Buchi (Option Excercise at a value of $0), James B. Weissman (Option Excercise at a value of $388 176), James B. Weissman (Sold 77 828 shares of value $2 317 278 ), Marc Kozin (Option Excercise at a value of $0), Martin Freed (Option Excercise at a value of $0), Patrick M. Gray (Option Excercise at a value of $0), Regina M. Paglia (Option Excercise at a value of $1 723 888), Regina M. Paglia (Sold 103 144 shares of value $3 282 098 ), Robert D. Ciappenelli (Option Excercise at a value of $468 300), Robert D. Ciappenelli (Sold 30 000 shares of value $1 110 000 ), Stephen J. Hoffman (Option Excercise at a value of $0), Stephen K. Doberstein (Option Excercise at a value of $0)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.